Clinical Trials Directory

Trials / Completed

CompletedNCT00614614

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,558 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
6 Weeks – 12 Weeks
Healthy volunteers
Accepted

Summary

The purpose of the study is to characterize the immunogenicity \& safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.

Detailed description

The purpose of this study is to evaluate the titer of antibody for serogroups A, C, Y and W-135 and the safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given to toddlers who were primed with GSK Biological's Hib-meningococcal vaccine 792014. In addition, this study will provide immunogenicity and safety data on the co-administration of Infanrix with meningococcal vaccine 134612 as compared to Infanrix administered alone. Depending on the group the subject is assigned to, one or two blood samples will be taken out of the subject's arm during the study. The protocol posting has been updated following a protocol amendment.

Conditions

Interventions

TypeNameDescription
BIOLOGICALGSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)One dose in the booster phase as intramuscular injection
BIOLOGICALGSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
BIOLOGICALInfanrix®One dose as intramuscular injection
BIOLOGICALActHIB®Three doses in the priming phase as intramuscular injection
BIOLOGICALPediarix®Three doses in the priming phase as intramuscular injection

Timeline

Start date
2008-02-13
Primary completion
2009-07-31
Completion
2009-09-17
First posted
2008-02-13
Last updated
2018-09-21
Results posted
2012-07-20

Locations

56 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00614614. Inclusion in this directory is not an endorsement.